Progress in determining the causes and treatment of multiple sclerosis

Nature

Volumn 399, Issue SUPPL., 1999, Pages

  Noseworthy, John H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; IMMUNOGLOBULIN G; INTERFERON BETA SERINE;

CORTICOSTEROID THERAPY; DISEASE SEVERITY; GENETIC SUSCEPTIBILITY; GENOME; HUMAN; HUMAN HERPESVIRUS 6; MULTIPLE SCLEROSIS; MYELINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RELAPSE; REMYELINIZATION; REVIEW; TREATMENT PLANNING; VIRUS INFECTION; ANIMAL; FORECASTING; GENETIC PREDISPOSITION; GENETICS; MYELIN SHEATH; NERVE FIBER; PATHOLOGY; VIROLOGY;

ANIMALS; AXONS; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; VIRUS DISEASES;

EID: 0033600078     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/399a040     Document Type: Review

References (101)

1. Risch, N. & Merikangas, K. The future of genetic studies of complex human diseases. Science 273, 1516-1517 (1996).
2. Weinshenker, B. G. et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112, 133-146 (1989).
3. Weinshenker, B. & Miller, D. in Frontiers in Multiple Sclerosis (eds Siva, A., Kesselring, J. & Thompson, A.) (Dunitz, London, 1998).
4. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis, principles, problems and perspectives. Brain 120, 865-916 (1997).
5. Noseworthy, J. MS clinical trials: old and new challenges. Semin. Neurol. 18, 377-388 (1998).
6. Cook, S., Rohowsky-Kochan, C., Bansil, S. & Dowling, P. Evidence for multiple sclerosis as an infectious disease. Acta Neurol. Scand. 161, 34-42 (1996).
7. Kurtzke, J. F. Epidemiologic evidence for multiple sclerosis as an infection. Clin. Microbiol. Rev. 6, 382-427 (1993).
8. Ebers, G. C. et al. A population-based study of multiple sclerosis in twins. N. Engl. J. Med. 315, 1638-1642 (1986).
9. Sibley, W. A., Bamford, C. R. & Clark, K. Clinical viral infections and multiple sclerosis. Lancet 1, 1313-1315 (1985).
10. Herndon, R. Herpesviruses in multiple sclerosis. Arch. Neurol. 53, 123-124 (1996).
11. Challoner, P. et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc. Natl Acad. Sci. USA 92, 7440-7444 (1995).
12. Liedtke, W., Malessa, R., Faustmann, P. & Eis-Hubinger, A. Human herpesvirus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis. J. Neurovirol. 1, 253-258 (1995).
13. Soldan, S. et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Med. 3, 1394-1397 (1997).
14. Merelli, E. et al. Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults, and children. J. Neurol. 244, 450-454 (1997).
15. Steinman, L. & Oldstone, M. More mayhem from molecular mimics. Nature Med. 3, 1321-1322 (1997).
16. Mason, D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19, 395-404 (1998).
17. Sanders, V. et al. Herpes simplex virus in postmortem multiple sclerosis brain tissue. Arch. Neurol. 53, 125-133 (1996).
18. Sanders, V., Felisan, S., Waddell, A. & Tourtellotte, W. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J. Neurovirol. 2, 249-258 (1996).
19. Mayne, M. et al. Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients. Ann. Neurol. 44, 391-394 (1998).
20. van Noort, J. et al. The small heat-shock protein αβ-crystallin as candidate autoantigen in multiple sclerosis. Nature 375, 798-801 (1995).
21. Compston, A. Genetic epidemiology of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 62, 553-561 (1997).
22. Sadovnick, A., Dyment, D. & Ebers, G. Genetic epidemiology of multiple sclerosis. Epidemiol. Rev. 19, 99-106 (1997).
23. Bulman, D. & Ebers, G. The geography of multiple sclerosis reflects genetic susceptibility. J. Trop. Geogr. Neurol. 2, 66-72 (1992).
24. Dyment, D., Sadovnick, A. & Ebers, G. Genetics of multiple sclerosis. Hum. Mol. Genet. 6, 1693-1698 (1997).
25. [Published erratum appears in Hum. Mol. Genet. 6, 2189 (1997).]
26. Little, C. A possible Mendelian explanation for a type of inheritance apparently non-Mendelian in nature. Science 40, 904-906 (1917).
27. Sadovnick, A., Ebers, G., Dyment, D., Risch, N. and the Canadian Collaborative Study Group. Evidence for genetic basis of multiple sclerosis. Lancet 347, 1728-1730 (1996).
28. Ebers, G., Sadovnick, A., Risch, N. and the Canadian Collaborative Study Group. A genetic basis for familial aggregation in multiple sclerosis. Nature 377, 150-151 (1995).
29. Waksman, B. More genes versus environment. Nature 377, 105-106 (1995).
30. Farrall, M. Mapping genetic susceptibility to multiple sclerosis. Lancet 348, 1674-1675 (1996).
31. Sawcer, S., Goodfellow, P. & Compston, A. The genetic analysis of multiple sclerosis. Trends Genet. 13, 234-239 (1997).
32. Zhang, H., Zhao, H. & Merikangas, K. Strategies to identify genes for complex diseases. Ann. Med. 29, 493-498 (1997).
33. Risch, N. Assessing the role of HLA-linked and unlinked determinants of disease. Am. J. Hum. Genet. 40, 1-14 (1987).
34. Haines, J. et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum. Mol. Genet. 7, 1229-1234 (1998).
35. Sawcer, S. et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genet. 13, 464-468 (1996).
36. Haines, J. et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. Nature Genet. 13, 469-471 (1996).
37. Ebers, G. et al. A full genome search in multiple sclerosis. Nature Genet. 13, 472-476 (1996).
38. Bell, J. & Lathrop, G. Multiple loci for multiple sclerosis. Nature Genet. 13, 377-378 (1996).
39. Kuokkanen, S. et al. A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. Nature Genet. 13, 477-480 (1996).
40. Kuokkanen, S. et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am. J. Hum. Genet. 61, 1379-1387 (1997).
41. Lucchinetti, C. F., Bruck, W., Rodriguez, M. & Lassmann, H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6, 259-274 (1996).
42. Storch, M. K, et al. Multiple sclerosis: in situ evidence for antibody-and complement-mediated demyelination. Ann. Neurol. 43, 465-471 (1998).
43. Compston, A. Remyelination in multiple sclerosis: a challenge for therapy. The 1996 European Charcot Foundation Lecture. Mult. Scler. 3, 51-70 (1997).
44. Trapp, B. et al. Axonal transaction in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
45. Wolinsky, J. S., Narayana, P. A. & Fenstermacher, M. J. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 40, 1764-1769 (1990).
46. Arnold, D. L., Matthews, P. M., Francis, G. & Antel, J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn. Reson. Med. 14, 154-159 (1990).
47. Arnold, D. L., Matthews, P. M., Francis, G. S., O'Connor, J. & Antel, J. P. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann. Neurol. 31, 235-241 (1992).
48. Davie, C. et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117, 49-58 (1994).
49. Matthews, P. et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin. Neurol. 18, 327-336 (1998).
50. Losseff, N. et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119, 2009-2019 (1996).
51. Losseff, N. et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119, 701-708 (1996).
52. Waxman, S. Demyelinating diseases - new pathological insights, new therapeutic targets. N. Engl. J. Med. 338, 323-325 (1998).
53. Bunge, M. B., Bunge, R. P. & Ris, H. Ultrastructural study of remyelination in an experimental lesion in the adult cat spinal cord. J. Biophys. Biochem. Cytol 10, 67-94 (1961).
54. Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R. & Cho, E.-S. Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol. 33, 137-151 (1993).
55. Zajicek, J. & Compston, A. Mechanisms of damage and repair in multiple sclerosis - a review. Mult. Scler. 1, 61-72 (1995).
56. Compston, A. Future options for therapies to limit damage and enhance recovery. Semin. Neurol. 18, 405-413 (1998).
57. Scolding, N. et al. A proliferative adult human oligodendrocyte progenitor. NeuroReport 6, 441-445 (1995).
58. Rodriguez, M. & Lennon, V. A. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol. 27, 12-17 (1990).
59. Noseworthy, J., O'Brien, P., van Engelen, B. & Rodriguez, M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from the Theiler's virus model to a randomized, double-blinded, placebo-controlled clinical trial. J. Neurol. Neurosurg. Psychiatry 57(Suppl.), 11-14 (1994).
60. Noseworthy, J., Weinshenker, B. & O'Brien, P. Intravenous immunoglobulin (IVIg) does not reverse recently acquired, apparently permanent weakness in multiple sclerosis (MS). Ann. Neurol. 42, A421 (1997).
61. Noseworthy, J. et al. Immunoglobulin administration (IVIg) does not reverse visual acuity loss in long-standing optic neuritis associated with multiple sclerosis. Ann. Neurol. 44, A504 (1996).
62. Bostock, H. & Sears, T. The internodal axon membrane: electrical excitability and continuous conduction in segmentai demyelination. J. Physiol. (Lond.) 280, 273-301 (1978).
63. Waxman, S. in Brain Plasticity, Advances in Neurology (eds Freund, H. J., Sabel, B. A. & Witte, O. W.) 109-120 (Lippincott-Raven, Philadelphia, 1997).
64. Rivera-Quinones, C. et al. Absence of neurological deficits following extensive demyelination in a class 1-deficient murine model of multiple sclerosis. Nature Med. 4, 187-193 (1998).
65. Ludwin, S. & Johnson, E. Evidence of a "dying back" gliopathy in demyelinating disease. Ann. Neurol. 9, 301-305 (1981).
66. Rodriguez, M. Virus-induced demyelination in mice: "dying back" of oligodendrocytes. Mayo Clin. Proc. 60, 433-438 (1985).
67. Ferguson, B., Matyszak, M., Esiri, M. & Petty, V. Axonal damage in acute multiple sclerosis lesions. Brain 120, 393-399 (1997).
68. Miller, D., Grossman, R., Reingold, S. & McFarland, H. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121, 3-24 (1998).
69. van Walderveen, M. A. A. et al. Correlating MR imaging and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/TE ("TI-weighted") spin-echo images. Neurology 45, 1684-1690 (1995).
70. Gass, A. et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann. Neurol. 36, 62-67 (1994).
71. Kidd, D. et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 60, 15-19 (1996).
72. Miller, D. Multiple sclerosis: use of MRI in evaluating new therapies. Semin. Neurol. 18, 317-325 (1998).
73. De Stefano, N. et al. Axonal damage correlated with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 121, 1469-1477 (1998).
74. Filippi, M., Rocca, M., Martino, G., Horsfield, M. & Comi, G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis, Ann. Neurol. 43, 809-814 (1998).
75. Goodkin, D. et al. A serial study of new MS lesions and the white matter from which they arise. Neurology 51, 1689-1697 (1998).
76. Kidd, D. et al. Central motor conduction time in progressive multiple sclerosis: correlations with MRI and disease activity. Brain 121, 1109-1116 (1998).
77. Noseworthy, J. H., Vandervoort, M. K., Hopkins, M. & Ebers, G. C. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop. Neurology 39, 977-981 (1989).
78. Noseworthy, J. H., Vandervoort, M. K., Wong, C. J. & Ebers, G. C. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 40, 971-975 (1990).
79. Noseworthy, J. H. et al. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 44, 16-20 (1994).
80. Petkau, J. Statistical methods for evaluating multiple sclerosis therapies. Semin. Neurol. 18, 351-375 (1998).
81. Stone, L. et al. Characterization of MRI response to treatment with Interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 49, 862-869 (1997).
82. Calabresi, P., Stone, L., Bash, C., Frank, J. & McFarland, H. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 48, 1446-1448 (1997).
83. Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 662-667 (1993).
84. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon b-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 45, 1277-1285 (1995).
85. Simon, J. et al. Magnetic resonance studies of intramuscular interferon b-1a for relapsing multiple sclerosis. Neurology 43, 79-87 (1998).
86. PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomised double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 352, 1498-1504 (1998).
87. Kappos, L. and the European Study Group on Interferon beta-1b in secondary-progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491-1497 (1998).
88. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655-661 (1993).
89. Jacobs, L. D. et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285-294 (1996).
90. Rudick, R. et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 49, 358-363 (1997).
91. Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268-1276 (1995).
92. Johnson, K. et al. Extended use of glatiramer acetate (Copaxone) is well toleraled and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50, 701-708 (1998).
93. Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S., Nahler, G., Mamoli, B. and the Austrian lmmunoglobulin in MS Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349, 589-593 (1997).
94. Achiron, A. et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 50, 398-402 (1998).
95. Sorensen, P. et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50, 1273-1281 (1998).
96. van den Noort, S. et al. National MS Society (NMSS): Disease Management Consensus Statement (National MS Society, New York, 1998).
97. Weinshenker, B. G. et al. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 112, 1419-1428 (1989).
98. Noseworthy, J. in A Problem-oriented Approach to Management and Treatment of Multiple Sclerosis. (eds Thompson, A., Polman, C. & Kohlfeld, R.) 177-193 (Dunitz, London, 1997).
99. Nose-worthy, J., O'Brien, P. and the Mayo Clinic-Canadian Cooperative MS Study Group. The Mayo Clinic Canadian Cooperative Trial of Sulfasalazine in active multiple sclerosis. Neurology 51, 1342-1352 (1998).
100. van Noort, J. Multiple sclerosis: an altered immune response or an altered stress response? J. Mol. Med. 74, 285-296 (1996).
101. Murray, P. et al. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J. Neurosci. 18, 7306-7314 (1998).